Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Company Info
Contact US
Spyre Therapeutics, Inc.
Technology
Overview
Contact US
Contributions
Contributors
Contributions
1 Contributions
1 / 1
1 / 1
0 Contributors
1 / 0
1 / 0
No authors found
Antibody
Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies
Spyre Therapeutics, Inc.
PR-12-24-NI-125
Dec 03, 2024
